<DOC>
	<DOCNO>NCT01561833</DOCNO>
	<brief_summary>This study pilot study sorafenib 400mg PO twice daily refractory T-cell lymphoma include peripheral T-cell lymphoma ( PTCL ) , angioimmunoblastic lymphadenopathy ( AILD ) , cutaneous T cell lymphoma ( CTCL ) , anaplastic large cell lymphoma ( ALCL ) transform T-cell lymphoma primary objective study biological effect multikinase inhibitor , sorafenib .</brief_summary>
	<brief_title>A Pilot Study Sorafenib Examining Biomarkers Refractory Relapsed T-Cell Lymphoma Patients</brief_title>
	<detailed_description>Primary objective : â€¢ To study biological effect sorafenib 400mg BID mitogen-activated protein kinase ( MAPK ) pathway , specifically inhibition extracellular signal-regulated kinase ( ERK ) phosphorylation , correlate clinical activity patient T-cell lymphoma . Secondary objective : - To observe clinical activity sorafenib 400mg BID determine response rate , progression free survival patient T-cell lymphoma . Duration response duration stable disease also measure . - To determine tolerability sorafenib patient T-cell lymphoma . Exploratory objective : - To observe effect sorafenib T-cell subset ( CD4/CD8 ratio , Tregs ) , effect sorafenib monocytoid population . - To observe effect sorafenib serum cytokine profile . - To observe effect sorafenib T-cell receptor pathway , i.e . Lck , ZAP-70 , Syk . - To observe change lymph node skin morphology include tumor cell infiltrate , vasculature , tumor microenvironment patient treat sorafenib perform serial biopsy lymph node skin .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologically confirm Tcell lymphoma include PTCL , AITL , CTCL , ALCL ( Alk+ , Alk ) , transform Tcell lymphomas Age &gt; 18 year old Measureable disease , define Cheson criterion ECOG Performance Status 0 1 Life expectancy &gt; 12 week Adequate bone marrow , liver renal function Patients hemoglobin &lt; 8.5g/dL , ANC 5001000/mm3 , platelet 50,00075,000/mm3 ( Grade 3 ) , whose cytopenia due bone marrow involvement Tcell lymphoma also eligible Prior treatment sorafenib , agent similar activity , i.e . bevacizumab , imatinib , sunitinib . Prior treatment allogeneic stem cell transplant Cardiac disease : Congestive heart failure &gt; class II NYHA .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>relapsed refractory T cell lymphoma</keyword>
</DOC>